Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our 30 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has 2,500 employees in 28 countries.
Cryoport is the leading provider of cryogenic logistics solutions for temperature-sensitive life sciences materials. With proprietary Cryoport Express® liquid nitrogen dry vapor shippers and packaging, innovative Cryoportal™ technology and cold chain logistics expertise, Cryoport is the preferred cryogenic logistics partner for the world’s largest shipping companies
Cell and gene therapies are quickly reaching an inflection point, showing great promise for the future of patient care. At GE Healthcare’s Cell Therapy Technologies, we strive to be at the forefront of this revolution by providing the right combination of customized tools, analytics, and support, while helping to standardize and optimize scale-out manufacturing technologies. Together we hope to realize the promise of these revolutionary new medicines and bring them into mainstream clinical use.
At Lonza Pharma & Biotech we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome, at the time when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, we can bring your next medicine to life.
NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.
Polyplus-transfection® SA is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in Eastern France, Polyplus-transfection® is ISO 9001-certified since 2002 and supplies its wide range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network.
Polyplus-transfection® reagents are involved in a growing number of clinical trials worldwide. In addition, Polyplus-transfection® holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery.
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.
We offer a full range of consulting, development and commercialisation services from a global network of offices in 38 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost and increasing quality – and our global team of experts has unparalleled experience in a broad range of therapeutic areas.
CellGenix is a premium supplier of high-quality reagents and tools for cell therapy applications. Our mission is to enable and accelerate safe and efficient transition of cell, gene and tissue engineered products from preclinical to post-approval clinical applications for the benefit of patients worldwide.
Fosun Kite Biotechnology Co., Ltd.
Fosun Kite Biotechnology Co., Ltd. is a joint venture established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma, Inc. (USA) in April 2017, Shanghai, China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.
In China, the company has obtained the comprehensive technology transfer and commercial license for Kite Pharma's CAR-T product Axicabtagene Ciloleucel (trade name Yescarta, the first CAR-T therapy approved by FDA for the treatment of non-Hodgkin lymphoma), and also has obtained the investigational new drug (IND) approval by the National Medical Products Administration (NMPA). In addition to Yescarta, Fosun Kite's R&D pipeline includes CAR-T/TCR-T programs in clinical phase and innovative programs in early R&D phase.
Schenzhen Pregene Biopharma
Founded in 2012, Schenzhen PREGENE is a high-tech enterprise invested by the National SME Development Fund and the Chinese Academy of Sciences. Deeply involved in the field of CAR-T cell medicine, Schenzhen PREGENE has a scientific research and industrialization team with strong academic background and rich practical experience. It has established a research and development platform and a CDMO platform for cell and gene therapy in Beijing and Shenzhen respectively.
Caprion Biosciences is a specialty laboratory CRO with an established track record in biomarkers, bioanalytical and immune monitoring services. Through its advanced immune monitoring platform, Caprion supports the development of vaccine and immunotherapy programs that require the characterization of innate and adaptive immunity. With its combined expertise in immune monitoring and mass spectrometry, Caprion brings in-depth knowledge of analytical and regulatory requirements and a commitment to open and real-time collaboration.
A critical factor facing the Cell Therapy industry is choosing technologies and partners that can deliver scale. There’s no other field of medicine that requires the level of mass customization of production and careful orchestration of production pathways that cell therapies demand. From sample collection through logistics, manufacturing and final transplantation, TrakCel’s proven technology integrates and orchestrates every aspect of your Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform.
Akron Biotech is an innovative biotechnology company with a strategic focus on supplying GMP-qualified raw materials and services to the regenerative medicine industry. Akron manufactures a range of products for cell therapy discovery, development, and commercialization. These products include growth factors, sera and purified proteins, custom-made cell culture media, tailored scaffolds with biomaterials, and proprietary cryopreservation formulations.